Pharma Pulse: FDA Greenlights Higher-Dose Wegovy with Pricing Commitments, and the State of the US Generics Market
Mar 20, 01:09 PM
Share
Subscribe
In today's Pharma Pulse, the FDA grants a 54-day fast-track approval for high-dose Wegovy under a new priority program
while a new report explores the economic pressures and chronic shortages destabilizing the U.S.
generics market
while a new report explores the economic pressures and chronic shortages destabilizing the U.S.
generics market